Reducing the toxicity of anticancer therapy: new strategies

This publication has 22 references indexed in Scilit:

• WR-1065, the active metabolite of amifostine (ethyol®), does not inhibit the cytotoxic effects of a broad range of standard anticancer drugs against human ovarian and breast cancer cells
  European Journal Of Cancer, 1996
• The need for cytoprotection
  European Journal Of Cancer, 1996
• Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer.
  Journal of Clinical Oncology, 1996
• The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine (Ethyol®)
  European Journal Of Cancer, 1996
• Amifostine (WR-2721) Protects Normal Haematopoietic Stem Cells Against Cyclophosphamide Derivatives' Toxicity Without Compromising Their Antileukaemic Effects
  European Journal Of Cancer, 1995
• Thiol and disulfide metabolites of the radiation protector and potential chemopreventive agent WR-2721 are linked to both its anti-cytotoxic and anti-mutagenic mechanisms of action
  Carcinogenesis: Integrative Cancer Research, 1995
• The radioprotector WR-2721 reduces neutron-induced mutations at the hypoxanthine-guanine phosphoribosyl transferase locus in mouse splenocytes when administered prior to or following irradiation
  Carcinogenesis: Integrative Cancer Research, 1992
• New Protective Agents for Bone Marrow in Cancer Therapy
  Cancer Investigation, 1991
• Protective effects of 2-[(aminopropyl)amino] ethanethiol against bleomycin and nitrogen mustard-induced mutagenicity in V79 cells
  International Journal of Radiation Oncology*Biology*Physics, 1986
• The radioprotector WR1065 reduces radiation-induced mutations at the hypoxanthine-guanine phosphoribosyl transferase locus in V79 cells
  Carcinogenesis: Integrative Cancer Research, 1985